Heron Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	154.9	144.29	127.04	107.67	86.35
Revenue Growth (YoY)	7.36%	13.57%	17.99%	24.70%	-2.59%
Cost of Revenue	41.35	38.65	65.11	54.87	46.02
Gross Profit	113.56	105.64	61.94	52.8	40.33
Selling, General & Admin	103.67	100.48	133.42	144.75	127.33
Research & Development	12.43	16.68	39.13	82.7	130.82
Total Operating Expenses	116.1	117.17	172.55	227.46	258.15
Operating Income	-2.54	-11.53	-110.62	-174.66	-217.83
Interest Income	1.95	3.55	3.36	1.64	0.43
Interest Expense	-9.61	-6.03	-3.87	-2.47	-2.41
Other Non-Operating Income (Expense)	-10	0.43	0.56	-6.53	-0.88
Total Non-Operating Income (Expense)	-17.66	-2.05	0.06	-7.37	-2.86
Pretax Income	-20.2	-13.58	-110.56	-182.02	-220.68
Net Income	-20.2	-13.58	-110.56	-182.02	-220.68
Net Income to Common	-20.2	-13.58	-110.56	-182.02	-220.68
Shares Outstanding (Basic)	167	152	138	109	98
Shares Outstanding (Diluted)	167	152	138	109	98
Shares Change (YoY)	9.35%	10.36%	26.87%	10.57%	8.48%
EPS (Basic)	-0.12	-0.09	-0.80	-1.67	-2.24
EPS (Diluted)	-0.12	-0.09	-0.80	-1.67	-2.24
Free Cash Flow	-27.91	-24.24	-60.33	-148.74	-206.38
Free Cash Flow Per Share	-0.17	-0.16	-0.44	-1.37	-2.10
Gross Margin	73.31%	73.21%	48.75%	49.04%	46.70%
Operating Margin	-1.64%	-7.99%	-87.07%	-162.21%	-252.27%
Profit Margin	-13.04%	-9.41%	-87.02%	-169.05%	-255.58%
FCF Margin	-18.02%	-16.80%	-47.49%	-138.14%	-239.01%
EBITDA	-0.22	-9.04	-107.72	-171.77	-214.81
EBITDA Margin	-0.14%	-6.26%	-84.79%	-159.53%	-248.77%
EBIT	-2.54	-11.53	-110.62	-174.66	-217.83
EBIT Margin	-1.64%	-7.99%	-87.07%	-162.21%	-252.27%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q